Echocardiographic evaluation of cardiac amyloidosis
Official title: Echocardiographic Characterization of Cardiac Amyloidosis: an Observational Study
Run by Fondazione Policlinico Universitario Agostino Gemelli IRCCS · NCT05760287 · Data updated 2026-11-12
This study is testing new heart imaging techniques to see if they can help tell cardiac amyloidosis apart from other heart problems and check how well tafamidis treatment can improve heart damage in patients.
Quick facts
| Study type | Observational |
|---|---|
| Ages | 18 Years and up |
| Sex | All |
| Enrollment | 255 (estimated) |
| Sponsor | Fondazione Policlinico Universitario Agostino Gemelli IRCCS Academic / other |
| Locations | 1 site (Roma, RM) |
| Status | Recruiting |
| Started | December 9, 2022 |
| Main results expected | December 2, 2030 |
| Study ends | February 2, 2031 |
| Registry record updated | September 4, 2026 |
| Trial ID | NCT05760287 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates are patients diagnosed with cardiac amyloidosis who meet the inclusion criteria set by the European Society of Cardiology.
✕Probably not a fit
Patients who do not have cardiac amyloidosis or those who decline participation will not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This observational study focuses on patients diagnosed with cardiac amyloidosis at the Fondazione Policlinico Universitario Agostino Gemelli IRCCS in Rome, Italy. It aims to utilize advanced echocardiographic techniques, including two- and three-dimensional speckle-tracking analysis, to differentiate cardiac amyloidosis from other similar heart conditions. Additionally, the study will assess the reversibility of myocardial damage in response to tafamidis treatment and explore new echocardiographic predictors of adverse cardiovascular outcomes.
Why it matters
Potential benefit: If successful, this study could enhance the diagnostic accuracy and treatment monitoring for patients with cardiac amyloidosis.
How similar studies have gone: While this approach is observational, similar studies utilizing advanced echocardiographic techniques have shown promise in improving diagnostic capabilities for cardiac conditions.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * patients with cardiac amyloidosis, defined according to the recommendations provided by the working group of the european society of cardiology, with clinical, electrocardiographic ed echocardiographic data and with at least one follow-up visit. Exclusion Criteria: * missing data * decline to the study participation
Where it's running
-
Fondazione Policlinico Gemelli IRCCS
Roma, Rm, Italy Recruiting
Study contacts
- Principal investigator: Francesca Graziani — Fondazione Policlinico Universitario Agostino Gemelli IRCCS
- Study coordinator: Francesca Graziani, MD
- Email: francesca.graziani@policlinicogemelli.it
- Phone: 00390630154432
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Liver and Coagulation Markers in ATTR Cardiac Amyloidosis
This study tests liver function and blood-clotting markers in people with ATTR-CA to see if they reflect disease severity and progression.
-
Cardiac Amyloidosis: See if Intracardiac Thrombi are Common on CT
This study tests whether a contrast-enhanced cardiac CT can reliably detect intracardiac thrombi in adults with cardiac amyloidosis.
-
Higher pacemaker rate for people with cardiac amyloidosis
This study will see if temporarily increasing the pacemaker rate improves heart-failure symptoms and exercise tolerance in adults with cardiac amyloidosis who already have pacemakers.
-
Using [64Cu]FBP8 PET/MR to find intracardiac blood clots in cardiac amyloidosis
We'll test whether a [64Cu]FBP8 PET/MR scan can find blood clots inside the heart of people with cardiac amyloidosis who have atrial fibrillation or atrial flutter.
-
Chest pain screening for hidden cardiac amyloidosis
We will test whether men over 65 who have chest pain but no coronary artery disease might have hidden cardiac amyloidosis using blood and urine tests, ECG and echocardiography, bone scintigraphy, and sometimes a heart biopsy.
-
Using advanced heart MRI to improve diagnosis and risk prediction for rare cardiomyopathies
This project tests whether advanced cardiac MRI techniques can help diagnose and predict future risk for people with rare heart muscle diseases like Danon, Fabry, cardiac amyloidosis, Noonan syndrome, and cardiac sarcoidosis.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.